Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-11-07
2006-11-07
Lewis, Patrick (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S043000, C514S046000, C514S047000, C514S048000
Reexamination Certificate
active
07132408
ABSTRACT:
This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis. The method comprises administering to a subject a pharmaceutical composition comprising a therapeutic effective amount of P2Y12receptor antagonist compound, wherein said amount is effective to bind the P2Y12receptors on platelets and inhibit ADP-induced platelet aggregation. The P2Y12receptor antagonist compounds useful for this invention include mononucleoside 5′-monophosphates, mononucleoside polyphosphates, and dinucleoside polyphosphates of general Formula I, or salts thereof. The present invention also provides novel compounds of mononucleoside 5′-monophosphates, mononucleoside polyphosphates, and dinucleoside polyphosphates. The present invention further provides pharmaceutical formulations comprising mononucleoside 5′-monophosphates, mononucleoside polyphosphates, or dinucleoside polyphosphates.
REFERENCES:
patent: 3321463 (1967-05-01), Moffatt et al.
patent: 4330550 (1982-05-01), Lautenschlager et al.
patent: 4621076 (1986-11-01), Kuzuya et al.
patent: 5049550 (1991-09-01), Zamecnik
patent: 5654285 (1997-08-01), Ingall et al.
patent: 5681823 (1997-10-01), Kim et al.
patent: 5721219 (1998-02-01), Ingall et al.
patent: 5747496 (1998-05-01), Cox et al.
patent: 5814609 (1998-09-01), Markland, Jr. et al.
patent: 5837861 (1998-11-01), Pendergast et al.
patent: 5900407 (1999-05-01), Yerxa et al.
patent: 5955447 (1999-09-01), Ingall et al.
patent: 6166022 (2000-12-01), Brown et al.
patent: 6323187 (2001-11-01), Yerxa et al.
patent: 6348589 (2002-02-01), Pendergast et al.
patent: 6596725 (2003-07-01), Peterson et al.
patent: 1407903 (1975-10-01), None
patent: WO 89/04321 (1989-05-01), None
patent: WO 92/01673 (1992-02-01), None
patent: WO 92/17488 (1992-10-01), None
patent: WO 94/08593 (1994-04-01), None
patent: WO 94/18216 (1994-08-01), None
patent: WO 97/03084 (1997-01-01), None
patent: WO 97/29456 (1997-08-01), None
patent: WO 98/03182 (1998-01-01), None
patent: WO 98/28300 (1998-07-01), None
patent: WO 98/34593 (1998-08-01), None
patent: WO 99/01138 (1999-01-01), None
patent: WO 99/32085 (1999-07-01), None
patent: WO 99/61012 (1999-12-01), None
patent: WO 00/33080 (2000-06-01), None
patent: WO 00/34283 (2000-06-01), None
patent: WO 00/39145 (2000-07-01), None
patent: WO 00/50024 (2000-08-01), None
patent: WO 01/19826 (2001-03-01), None
patent: WO 01/36421 (2001-05-01), None
patent: WO 01/39781 (2001-06-01), None
patent: WO 02/16381 (2002-02-01), None
Moffatt, et al., “Nucleoside polyphosphates . . . ”, Journal of the American Chemical Society (1958), 80, 3756-61.
International Search Report PCT/US01/41818, Mar. 11, 2002, PCT.
Hamilton, A. et al., “Design of Substrate-Site-Directed Inhibitors of Adenylate Kinase and Hexokinase. Effect of Substrate Substituents on Affinity for the Adenine Nucleotide Sites”,J. Med. Chem.,19:1371-1377 (1976).
Hiratsuka T., “Affinity Labeling of the Myosin ATPase with Riobse-Modified Fluroescent Nucleotides and Vanadate”,J. Biochem.,96:147-154 (1984).
Martin, P. et al., “Structure-Activity Studies of Analogs of β,γ-Methylene-ATP at P2x-Purinoceptors in the Rabbit Ear Central Artery”,Drug Development Research,36: 153-165 (1995).
Metzker, M. et al., “Termination of DNA synthesis by novel3′-modified-deoxyribonucleoside 5′-triphophate”,Nucleic Acids Research,22:4259-4267 (1994).
Pelicano, H. et al., “Study of the substrate-binding properties of bovine liver adenosine kinase and inhibition by fluorescent nucleoside analogues”,Eur. J. Biochem.,248:930-937 (1997).
Richard, J. and Frey, P.A., “Stereochemical Course of Thiophosphoryl Group Transfer Catalyzed by Adenylate Kinase”,J. Am. Chem. Soc.,100:7757-7758 (1978).
Sekine, M. et al., “New Type of Chemical Oxidative Phosphorylation: Activation of Phosphonate Function by Use of Triisoprobylbenzenesulfonyl Chloride”,Tetrahedron Letters,1145-1148 (1997).
Zatorski, A. et al., “Chemical Synthesis of Benzamide Adenine Dinucleotide: Inhibition of Inosine Monophosphate Dehydrogenase (Types I and II)”,Journal of Medicinal Chemistry, American Chemical Society,39:2422-2426 (1996).
Alessi, D. et al., “Synthesis and Properties of a Conformationally Restricted Spin-Labeled Analog of ATP and Its Interaction with Myosin and Skeletal Muscle”Biochemistry(1992), 31(34), 8043-54.
Antiplatelet Trialists'Collaberation., “Collaborative overview of randomised trials of antiplatelet therapy-I : Prevention of Death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients,”Br. Med. J.308: 81-106 (1994).
Antiplatelet Trialists'Collaberation., “Collaborative overview of randimised trials of antiplatelet therapy-II : maintenance of Vascular graft or arterial patency by antiplatelet therapy,”Br. Med. J.308: 159-168 (1994).
Antman, E, for The TIMI 9a investigators, “Hirudin in Acute Myocardial Infarction,” ,Circulation,90(4):1624-1630 (1994).
Bernat, A., et al., “Effect of Various Antiplatelet Agents on Acute Arterial Thrombosis in the Rat,”Thromb. Haemostas.(1993) 70(5):812-816.
Bujalowski, W. et al., “Structural Characteristics of the Nucleotide-Binding Site ofEscherichia coliPrimary Replicative Helicase DnaB Protein. Studies with Ribose and Base-Modified Fluorescent Nucleotide Analogs”Biochemistry(1994), 33(15), 4682-94.
Bush, L., et al., “Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canie coronary arteries,” Circulation 69(6):1161-1170, (1984).
Cardullo, R. A. et al., “Synthesis, Purification, and Characterization of 2,4,6-Trinitrophenyl-UDP-galactose: A Fluorescent Substrate for Galactosyltransferase”Analytical Biochemistry(1990), 188(2), 305-9.
Carvalho-Alves, P. et al., “Stoichiometric Photlabeling of Two Distinct Low and High Affinity Nucleotide Sites in Sarcoplasmic Reticulum ATPase”Journal of Biological Chemistry(1985), 260(7), 4282-7.
Chapal, J. et al., “Comparitive effects of adenosine-5′-triphosphate and related analogs on insulin secretion from the rat pancreas”Fundamental&Clinical Pharmacology(1997), 11(6), 537-545.
Folts, J. et al., “Platelet Aggregation in Partially Obstructed Vessels and its Elimination with Asprian,” Circulation 54(3):365-370 (1976).
Frederick, L.G., et al., “The Protective Dose of the Potent GPIIb/IIIa Antagonist SC-54701A is Reduced When Used in Combination with Asprian and Heparin in a Canie Model of Coronary Artery Thrombosis,” Circulation 93(1):129-134 (1996).
Geiger, J., et al., “Specific Impairment of Human Platelet P2Y ac ADP Receptor-Mediated Signaling by the Antiplatelet Drug Clopidogrel,”Aterioscler. Thromb. Vasc. Biol.19:2007-2011 (1999).
Hass, W., et al., “A Randomized Trial Comparing Ticlopidine Hydrochloride with Asprian for the Prevention of Stroke for High-Risk Patients,”N. Engl. J. Med.,321(8):501-507 (1989).
Herbert, J.M. et al., Inhibitory Effect of Clopidogrel on Platelet Adhesion and Intimal Proliferation After Arterial Injury in Rabbits,Arterioscl. Thromb.(1993) 13(8):1171-1179.
Hiratsuka, Toshiaki, “Biological Activities and Spectroscopic Properties of Chromophoric and Fluorescent Analogs of Adenine Nucleoside and Nucleotides, 2′,3′-O-(2,4,6-Trinitrocyclohexadienylidene) Adenosine Derivatives”Biochemicha et Biophysica Acta(1982), 719(3), 509-17.
Hiratsuka, Toshiaki “Monitoring the Myosin ATPase Reaction Using a Sensitive Fluorescent Probe: Pyrene-Labeled ATP”Biophysical Journal(1997), 72(2, Pt. 1), 843-849.
Hourani, et al., The Platelet ADP Receptors Meeting, La Thuile, Italy, Mar. 29-31, 2000.
Humphries, R.G., et al., “Pharmacological profile of the n
Bednarski Krzysztof
Boyer José L.
Douglass, III James G.
Olins Gillian M.
Shaver Sammy R.
Howrey LLP
Inspire Pharmaceuticals Inc.
Kung Viola T.
Lewis Patrick
University of North Carolina
LandOfFree
Composition and method for inhibiting platelet aggregation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and method for inhibiting platelet aggregation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and method for inhibiting platelet aggregation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3657693